Answers are grounded in this paper and cite their sources.
HEALTH CARE POLICY AND LAW Potential Medicare Savings From Generic Substitution and Therapeutic Interchange of ACE Inhibitors and Angiotensin-II-Receptor Blockers Prescription drug spending accounts for an increasing share of US health care costs.1 Spending can be decreased by substituting generic drugs for identical brand-name drugs (generic substitution) or for brand-name drugs with similar effect (therapeutic interchange).2 We estimated the potential cost savings for Medicare from generic substitution and therapeutic interchange of angiotensin converting enzyme inhibitors (ACEIs) and angiotensin-II-receptor blockers (ARBs).
No takes yet. Share an insight, caveat, or question.
Growdon et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: